Bonti launches Phase II trial of EB-001 for musculoskeletal pain

US-based biotechnology firm Bonti has launched a Phase II clinical trial (LANTERN-1) of EB-001 to treat patients with musculoskeletal pain.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news